Clinical Trials Logo
  1. Home
  2. Arthritis, Rheumatoid
  3. NCT01313858
  4. Details
NCT01313858 Clinical Trial

A Study to Investigate the Use of Simponi® in Participants With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis (P06554)

Arthritis, Rheumatoid Clinical Trial

— GO-NICE  

Official title:
Non-Interventional Study Investigating the Use of Simponi® in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT01313858
Other study ID # P06554
Secondary ID
Status Completed
Phase N/A
First received March 10, 2011
Last updated October 25, 2015
Start date April 2010
Est. completion date September 2015

Study information
Verified date October 2015
Source Merck Sharp & Dohme Corp.
Contact n/a
Is FDA regulated No
Health authority Germany: Paul-Ehrlich-Institut
Study type Observational

Clinical Trial Summary

This is a study to assess the use of Simponi® in participants with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.

Recruitment information / eligibility
Status Completed
Enrollment 1521
Est. completion date September 2015
Est. primary completion date September 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Has rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis and treatment with Simponi® by autoinjector device is to be initiated for the first time

Exclusion Criteria:

- No specific exclusion criteria

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Intervention

Drug:
• Simponi®
50 mg subcutaneous injection once monthly

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Merck Sharp & Dohme Corp.

Outcome
Type Measure Description Time frame Safety issue
Primary Change in Clinical Global Impression (CGI) Disease Status Baseline and Month 3 No
Primary Change in Clinical Global Impression (CGI) Disease Status Baseline and Month 6 No
Primary Change in Clinical Global Impression (CGI) Disease Status Baseline and Month 9 No
Primary Change in Clinical Global Impression (CGI) Disease Status Baseline and Month 12 No
Primary Change in Clinical Global Impression (CGI) Disease Status Baseline and Month 15 No
Primary Change in Clinical Global Impression (CGI) Disease Status Baseline and Month 18 No
Primary Change in Clinical Global Impression (CGI) Disease Status Baseline and Month 21 No
Primary Change in Clinical Global Impression (CGI) Disease Status Baseline and Month 24 No
Secondary Change in FFbH (Funktionsfragebogen Hannover) Questionnaire Score Baseline and Month 3 No
Secondary Change in FFbH (Funktionsfragebogen Hannover)Questionnaire Score Baseline and Month 6 No
Secondary Change in FFbH (Funktionsfragebogen Hannover) Questionnaire Score Baseline and Month 9 No
Secondary Change in FFbH (Funktionsfragebogen Hannover) Questionnaire Score Baseline and Month 12 No
Secondary Change in FFbH (Funktionsfragebogen Hannover) Questionnaire Score Baseline and Month 15 No
Secondary Change in FFbH (Funktionsfragebogen Hannover) Score Baseline and Month 18 No
Secondary Change in FFbH (Funktionsfragebogen Hannover) Questionnaire Score Baseline and Month 21 No
Secondary Change in FFbH (Funktionsfragebogen Hannover) Questionnaire Score Baseline and Month 24 No
Secondary Change in Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Score Baseline and Month 3 No
Secondary Change in Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Score Baseline and Month 6 No
Secondary Change in Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Score Baseline and Month 12 No
Secondary Change in Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Score Baseline and Month 18 No
Secondary Change in Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Score Baseline and Month 24 No
See also
  Status Clinical Trial Phase
Terminated NCT01682512 - Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis Phase 3
Completed NCT00539760 - A Phase I Rheumatoid Arthritis Study in Healthy Volunteers Phase 1
Active, not recruiting NCT03312465 - Anatomical Shoulder Domelock System Study
Completed NCT01208181 - A Two-Part, 12-Week Study of Etoricoxib as a Treatment for Rheumatoid Arthritis (RA) (MK-0663-107) Phase 3
Completed NCT03254810 - Comparison of the Safety and PK of SYN060 to Humira® in Healthy Adult Subjects Phase 1
Completed NCT01711814 - A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study Phase 2
Completed NCT03315494 - Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SKI-O-703 in Healthy Volunteers Phase 1
Withdrawn NCT03241446 - Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis (RA) Phase 1
Completed NCT02748785 - MTX Discontinuation and Vaccine Response Phase 4
Completed NCT02553018 - Comparison of Compliance and Evolution of Functional Capacity of Patients With Rheumatoid Arthritis Treated by Methotrexate Either by Auto-injector or by Conventional Sub-cutaneous Syringe Phase 3
Active, not recruiting NCT02260778 - Treat-to-target in RA: Collaboration To Improve adOption and adhereNce N/A
Completed NCT02569736 - Characterization of the Effect of Tocilizumab in Vivo and in Vitro on T Follicular Helper Cells in Rheumatoid Arthritis Patients and Consequence on B Cells Maturation
Completed NCT01750931 - This Study is Randomised, Single Oral Dose Bioequivalence Study of Meloxicam GSK 15 MG Tablets. Phase 2
Withdrawn NCT01204138 - Concomitant Use of Apremilast for the Treatment of Active RA Despite TNF-Inhibition and Methotrexate- CATARA Phase 2
Not yet recruiting NCT01154647 - Pain Inhibition in Patients With Rheumatoid Arthritis and Central Sensitivity Syndromes N/A
Completed NCT00913458 - Study Evaluating Etanercept Plus Methotrexate in Early Rheumatoid Arthritis Phase 4
Completed NCT00975130 - Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2) Phase 3
Completed NCT00973479 - An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy Phase 3
Completed NCT00660647 - Optimized Treatment Algorithm for Patients With Early Rheumatoid Arthritis (RA) Phase 3
Completed NCT00550446 - A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis Phase 2